Qualigen Therapeutics (NASDAQ:AIXC) Posts Earnings Results

Qualigen Therapeutics (NASDAQ:AIXC) issued its quarterly earnings results on Friday. The company reported ($0.21) EPS for the quarter, FiscalAI reports.

Qualigen Therapeutics Stock Performance

AIXC traded down $0.00 on Friday, hitting $0.82. The company had a trading volume of 34,139 shares, compared to its average volume of 70,411. The stock has a market cap of $16.64 million, a price-to-earnings ratio of -0.13 and a beta of 0.53. The stock’s fifty day simple moving average is $1.07. Qualigen Therapeutics has a 1 year low of $0.62 and a 1 year high of $8.81.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Qualigen Therapeutics in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.